Article Text

Download PDFPDF

686 Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager (bsTCE), confirmed in the clinical setting
  1. Roeland Lameris1,
  2. Jurjen Ruben2,
  3. Rob Roovers2,
  4. Arnon Kater1,
  5. Thilo Riedl2,
  6. Victoria Iglesias2,
  7. Annemiek Broijl3,
  8. Ilse Tuinhof2,
  9. Sanjana Umarale2,
  10. Anton Adang2,
  11. Tanja de Gruijl1,
  12. Paul Parren2,
  13. Benjamin Winograd2 and
  14. Hans Van der Vliet4
  1. 1Amsterdam UMC, Amsterdam, Netherlands
  2. 2LAVA Therapeutics N.V, Utrecht, Netherlands
  3. 3Erasmus MC, Rotterdam, Netherlands
  4. Amsterdam UMC, LAVA Therapeutics N.V., Amsterdam, Netherlands


Background LAVA-051, a CD1d-targeting first-in-class bispecific single domain antibody (27 kDa), was brought into the clinic based on its high potency antitumor activity through dual engagement of Vγ9Vδ2-T and iNKT cells, and a low risk of cytokine release syndrome (CRS).

Methods A phase 1 study using LAVA-051 is ongoing in patients with relapsed/refractory MM or CLL to determine the recommended phase 2 dose (RP2D). This study has been approved by relevant ethics committees (NCT04887259). A panel of specific pharmacodynamic assays is included to determine the pattern of change in the binding of LAVA-051 to patients’ peripheral blood Vγ9Vδ2-T cells (i.e. Vγ9Vδ2-TCR occupancy) and in the frequency and activation status of Vγ9Vδ2-T and iNKT cells in circulation. Data presented are focused on the comparison of clinical to pre-clinical observations.

Results LAVA-051 triggers Vγ9Vδ2-T and iNKT cell mediated pro-inflammatory cytokine production, proliferation and antitumor activity in in vitro and ex vivo assays using patient CD1d+ AML, CLL and MM cells. In addition, LAVA-051 induced a strong anti-tumor effect in vivo in a CDX model using NSG mice with intermittent dosing. In a non-human primate (NHP) model utilizing a cross-reactive CD1d-Vγ9 bsTCE there was clear observation of Vγ9Vδ2-T cell engagement as reflected by a (temporary) decrease in circulating Vγ9Vδ2-T cells after dosing and concomitant upregulation of the activation marker CD69. As of July 2022, doses up to 100x the starting dose have been evaluated as safe in the clinical setting with 8 patients treated in total; importantly no CRS was observed. A similar temporary decrease in Vγ9Vδ2-T cells with consistent upregulation of activation markers (CD25 and CD69) as was seen in the NHP study has been observed in the clinic. In the NHP model, dose-dependent binding of the bsTCE to peripheral blood Vγ9-T cells was observed up to several days after injection. Similarly in the clinic, Vγ9Vδ2-TCR occupancy was shown to increase with higher dose cohorts with a current maximum of 20.9% receptor occupancy after dosing (45µg). The frequency and activation status of iNKT cells has been assessable in the clinic and will continue to be evaluated with escalating doses.

Conclusions LAVA-051 has demonstrated on-mechanism pharmacodynamics in the clinic, reflective of pre-clinical findings. The differentiating importance of these pharmacodynamic parameters with any correlating preliminary antitumor activity will be further elucidated in determining the RP2D and schedule; updated comparative data will be presented at the congress.

Trial Registration NCT04887259

Ethics Approval This study has been approved by relevant ethics committees in the Netherlands, Spain and Italy (EUDRACT: 2020-004583-26). Informed consent was obtained from all patients prior to their participation.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.